Katy Marshall

DocwireNews

The randomized, <a href="https://ascopost.com/news/october-2023/cabozantinib-for-pretreated-patients-with-advanced-neuroendocrine-tumors-cabinet-trial/">phase 3 CABINET trial</a> analyzed the benefits of cabozantinib for previously treated patients with advanced pancreatic neuroendocrine tumors (pNET). Researchers found that cabozantinib can improve the progression-free survival (PFS) rate for patients.Dr. Jennifer Chan, of the Dana-Farber Cancer Institute, <a href="https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/82">presented the double-blinded study</a> at the European Society for Medical Oncology Congress 2023.Researchers evaluated the efficacy of cabozantinib in patients with advanced pNET or advanced extrapancreatic neuroendocrine tumors (epNET).Participating patients had to demonstrate measurable disease determined using the Response Evaluation Criteria in Solid Tumors version 1.1. They also had to show disease progression following a minimum of 1 US Food and Drug Administration&ndash;approved line of prior therapy, not including somatostatin analogs.The 290 patients participating in the study were placed into the pNET group (n=93) or the epNET group (n=197) based on their diagnosis. Investigators randomly selected patients in each group, using a 2:1 ratio, to receive either cabozantinib 60 mg daily or placebo daily.In each group, more than half of the patients previously underwent treatment with everolimus or prior Lu-177 dotatate.The study&rsquo;s primary end point was PFS. Secondary end points included response rate and overall survival. If a patient in the placebo group experienced disease progression, they were unblinded and allowed to switch treatment to open-label therapy with cabozantinib.In the epNET group, with a median follow-up of 13.9 months, patients who took cabozantinib experienced a median PFS rate of 8.3 months in contrast with 3.2 months for those who took placebo. In the pNET group, with a median follow-up of 16.7 months, patients who received cabozantinib experienced a median PFS rate of 11.4 months, compared with 3.0 months for the placebo group.Researchers concluded that physicians could use cabozantinib as a new treatment for patients with previously treated, progressive neuroendocrine tumors. &ldquo;Given that there is no standard treatment for patients with progressive disease, these results showing notable improvements in progression-free survival are highly encouraging for patients and their physicians,&rdquo; said Chan.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

CABINET: Does Cabozantinib Benefit Patients With Advanced Pancreatic Neuroendocrine Tumors?

ESMO Congress 2023

Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe